CSL Limited yesterday reported
10% drop in net profit to $1.6
billion for the twelve months to
30 Jun, with ceo Paul Perreault
also foreshadowing a slower than
expected rebound next year.
Perrault highlighted CSL’s core
blood plasma products as well as
“strong growth prospects from
increasing diagnosis rates of rare
immune diseases”.
He confirmed CSL currently
spends almost $1b a year on R&D.The above article was sent to subscribers in Pharmacy Daily's issue from 18 Aug 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 Aug 16
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.